3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
32
Triple Negative Breast Neoplasms
26
Carcinoma, Transitional Cell
9
Neoplasm Metastasis
8
Carcinoma, Non-Small-Cell Lung
8
Urinary Bladder Neoplasms
7
Lung Neoplasms
4
Endometrial Neoplasms
3
Brain Neoplasms
3
Small Cell Lung Carcinoma
2
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Advanced Breast Cancer
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urothelial Bladder Carcinoma
1
Triple Negative Locally Advanced Non-resectable Breast Cancer
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm, Residual
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Interventions
Magnetic Resonance Spectroscopy
11
trametinib
8
selpercatinib
7
pembrolizumab
7
dabrafenib
7
Nivolumab
7
Iodine-131
6
lenvatinib
5
Specimen Handling
5
Biopsy
5
cabozantinib
4
Vemurafenib
4
Iodine-124
4
larotrectinib
3
durvalumab
3
binimetinib
3
anlotinib
3
Ipilimumab
3
Immunoglobulin G
3
Fluorodeoxyglucose F18
3
Disulfides
3
Cyclophosphamide
3
Cetuximab
3
vandetanib
2
ulixertinib
2
pralsetinib
2
omipalisib
2
defactinib
2
copanlisib
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
sacituzumab govitecan
×
1 year
×
Clear all
NCT06923826
2025-07-25
TROP2
National University Hospital, Singapore
Phase 2
Recruiting
32 enrolled